Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Thymoglobulin Versus Alemtuzumab Versus Daclizumab in Living Donor Renal Transplantation

This study has been completed.
Sponsor:
Collaborator:
Hoffmann-La Roche
Information provided by:
University of Miami
ClinicalTrials.gov Identifier:
NCT01046955
First received: January 11, 2010
Last updated: NA
Last verified: May 2008
History: No changes posted
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2008
  Primary Completion Date: April 2007 (Final data collection date for primary outcome measure)